Literature DB >> 7573093

The prevalence of side effects with regular and sustained-release nicotinic acid.

L W Gibbons1, V Gonzalez, N Gordon, S Grundy.   

Abstract

PURPOSE: To document the prevalence and nature of the side effects that occur with the use of regular and sustained-release nicotinic acid in everyday clinical practice. PATIENTS AND METHODS: One hundred and ten patients seen in a private medical clinic who were given 133 separate trials of nicotinic acid during a 5-year period. The occurrence of side effects, particularly those severe enough to warrant discontinuing the drug, were carefully monitored.
RESULTS: Forty-three percent of individuals given regular nicotinic acid and 42% of those given sustained-release nicotinic acid were forced to discontinue the medication because of side effects; some of these side effects necessitating discontinuing nicotinic acid did not occur until the patient had been taking the drug for 1 or 2 years.
CONCLUSION: Nicotinic acid in both regular and sustained-release forms is a powerful drug when used in doses needed to treat lipid disorders and causes disturbing side effects a very high percentage of the time. No one should use nicotinic acid in these doses without continued careful supervision of a physician.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7573093     DOI: 10.1016/s0002-9343(99)80185-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

Review 1.  A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.

Authors:  Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2010-04       Impact factor: 7.616

Review 2.  How well tolerated are lipid-lowering drugs?

Authors:  B Tomlinson; P Chan; W Lan
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Nutritional Supplementation with Essential Amino Acids and Phytosterols May Reduce Risk for Metabolic Syndrome and Cardiovascular Disease in Overweight Individuals with Mild Hyperlipidemia.

Authors:  Robert H Coker; Nicolaas E Deutz; Scott Schutzler; Marjorie Beggs; Sharon Miller; Robert R Wolfe; Jeanne Wei
Journal:  J Endocrinol Diabetes Obes       Date:  2015-04-15

4.  Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease.

Authors:  Elisa Fabbrini; B Selma Mohammed; Kevin M Korenblat; Faidon Magkos; Jennifer McCrea; Bruce W Patterson; Samuel Klein
Journal:  J Clin Endocrinol Metab       Date:  2010-04-06       Impact factor: 5.958

Review 5.  Rational approach to the treatment for heterozygous familial hypercholesterolemia in childhood and adolescence: a review.

Authors:  L Iughetti; B Predieri; F Balli; S Calandra
Journal:  J Endocrinol Invest       Date:  2007-09       Impact factor: 4.256

6.  Nicotinic acid promotes sleep through prostaglandin synthesis in mice.

Authors:  Éva Szentirmai; Levente Kapás
Journal:  Sci Rep       Date:  2019-11-19       Impact factor: 4.379

Review 7.  The mechanism and mitigation of niacin-induced flushing.

Authors:  V S Kamanna; S H Ganji; M L Kashyap
Journal:  Int J Clin Pract       Date:  2009-09       Impact factor: 2.503

Review 8.  Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin.

Authors:  Anbu Pandian; Anjali Arora; Laurence S Sperling; Bobby V Khan
Journal:  Vasc Health Risk Manag       Date:  2008
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.